CureVac N.V. (CVAC)
After hours:
| Previous close | 11.68 |
| Open | 11.47 |
| Bid | 11.00 x 900 |
| Ask | 11.49 x 1000 |
| Day's range | 11.01 - 11.83 |
| 52-week range | 5.63 - 20.49 |
| Volume | |
| Avg. volume | 990,754 |
| Market cap | 2.105B |
| Beta (5Y monthly) | 2.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings date | 26 Apr 2023 - 01 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.62 |
- EQS Group
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Issuer: CureVac / Key word(s): Personnel01.02.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Welcomes Myriam Mendila as New Chief Development Officer Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experienceTÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribo
- EQS Group
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®
Issuer: CureVac / Key word(s): Patent31.01.2023 / 14:12 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis® CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technologyTÜBINGEN, Germany/ BOSTON, USA – January 31, 2023 – CureVac N.V
- EQS Group
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features)
Issuer: CureVac / Key word(s): Study30.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants i
